文献速递血栓与止血

HLA-DRB1与因子VIII结合是非重型血友病抑制物产生的危险因素:一项病例对照研究

HLA-DRB1-factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study.
PubMed 文献 · Blood Adv · 2018-01-01

该病例对照研究纳入20例产生抑制物的非重型血友病A患者和37例未产生抑制物的对照,分析预测的HLA-DRB1与因子VIII肽结合及新抗原组合与抑制物产生的关系。发现超过10个新HLA-DRB1等位基因-治疗FVIII肽组合与抑制物产生相关(校正OR 4.1,95%CI 1.1-15.0)。p.Arg612Cys和p.Arg2169His突变患者中该新组合水平较高。

要点

  • 超过10个新HLA-DRB1等位基因-治疗FVIII肽组合与抑制物产生相关(校正OR 4.1,95%CI 1.1-15.0)。
  • p.Arg612Cys和p.Arg2169His突变的病例与对照均显示高水平新HLA-DRB1-治疗FVIII肽组合。
  • 评估治疗FVIII以新方式呈递给T细胞的可能性可能有助于理解并最终降低非重型血友病患者的抑制物风险。

核心结论

  • 超过10个新HLA-DRB1等位基因-治疗FVIII肽组合与抑制物产生相关(校正OR 4.1,95%CI 1.1-15.0)。
  • 评估治疗FVIII以新方式呈递给T细胞的可能性可能有助于理解并最终降低非重型血友病患者抑制物风险,尤其对p.Arg612Cys和p.Arg2169His以外的F8突变患者。

研究设计与样本

  • 病例对照研究,纳入20例非重型血友病A抑制物阳性病例(抑制物滴度≥1.0 BU/mL两次或一次后接受免疫耐受诱导)和37例接受FVIII输注但未产生抑制物的对照。
  • 使用MHC-II结合预测工具(https://www.iedb.org)确定内源性FVIII和治疗FVIII的结合亲和力及核心结合。
  • 若治疗FVIII肽被预测为结合并呈递与内源性FVIII不同的T细胞受体表面,则视为新肽。

主要发现

  • 超过10个新HLA-DRB1等位基因-治疗FVIII肽组合与抑制物产生相关(校正OR 4.1,95%CI 1.1-15.0)。
  • p.Arg612Cys和p.Arg2169His突变的病例与对照均显示高水平新HLA-DRB1-治疗FVIII肽组合。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Development of anti-factor VIII (FVIII) inhibitory antibodies (inhibitors) is the most significant treatment complication of hemophilia A. Characteristics of the interaction between major histocompatibility complex (MHC) class II and FVIII peptides may influence FVIII antigen presentation to T cells and subsequent inhibitor development. We analyzed predicted HLA-DRB1, a subset of MHC class II, and FVIII peptide binding and its association with inhibitor development among subjects with nonsevere hemophilia A, including 20 cases (inhibitor titer ≥ 1.0 BU/mL on 2 occasions or on 1 occasion with subsequent immune tolerance induction) and 37 controls (who had received FVIII infusions and did not develop inhibitor). Using the MHC-II Binding Predictions Tool (https://www.iedb.org), the binding affinity and core binding were determined for endogenous FVIII (eFVIII) and treatment FVIII (tFVIII). A tFVIII peptide was considered novel if it was predicted to bind and present a surface to the T-cell receptor that was unique from that presented by eFVIII. Having >10 novel HLA-DRB1 allele-tFVIII peptide combinations was associated with inhibitor development (adjusted odds ratio, 4.1; 95% confidence interval, 1.1-15.0). Cases and controls with p.Arg612Cys and p.Arg2169His demonstrated a high level of novel HLA-DRB1-tFVIII peptide combinations. Assessing the likelihood that tFVIII is presented to T cells in a novel fashion may be useful for understanding and ultimately reducing the risk for inhibitor development among patients with nonsevere hemophilia, particularly those with F8 mutations other than p.Arg612Cys and p.Arg2169His.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kempton CL, Payne AB. HLA-DRB1-factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study. Blood Adv. 2018. PMID: 30037801. doi:10.1182/bloodadvances.2018019323

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。